Merrimack Pharmaceuticals Inc (OQ:MACK)

Business Focus: Biotechnology & Medical Research

May 05, 2022 04:30 pm ET
Merrimack Reports First Quarter 2022 Financial Results
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its first quarter 2022 financial results for the period ended March 31, 2022.
Mar 09, 2022 04:30 pm ET
Merrimack Reports Full Year 2021 Financial Results
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its full year 2021 financial results for the period ended December 31, 2021.
Nov 04, 2021 05:00 pm ET
Merrimack Reports Third Quarter 2021 Financial Results
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its third quarter 2021 financial results for the period ended September 30, 2021.
Aug 05, 2021 04:30 pm ET
Merrimack Reports Second Quarter 2021 Financial Results
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) (“Merrimack” or the “Company”) today announced its second quarter 2021 financial results for the period ended June 30, 2021.
May 28, 2021 08:00 am ET
180 Life Sciences Corp. Announces the Appointment of Russell T. Ray, MBA and Teresa DeLuca MD, MBA to Board of Directors
180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that...
Mar 10, 2021 06:00 pm ET
Merrimack Reports Full Year 2020 Financial Results
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its full year 2020 financial results for the period ended December 31, 2020.
Nov 05, 2020 08:20 am ET
Merrimack Reports Third Quarter 2020 Financial Results
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its third quarter 2020 financial results for the period ended September 30, 2020.
Aug 07, 2020 08:20 am ET
Merrimack Reports Second Quarter 2020 Financial Results
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its second quarter 2020 financial results for the period ended June 30, 2020.
May 07, 2020 06:10 pm ET
Merrimack Reports First Quarter 2020 Financial Results
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its first quarter 2020 financial results for the period ended March 31, 2020.
Apr 02, 2020 08:30 am ET
Merrimack Divests Early Stage Asset for $2.25 Million; Provides Strategy Update
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced receipt of $2.25 million in connection with the closing of a transaction in which the Company sold certain assets related to its preclinical nanoliposome programs to Celator Pharmaceuticals, Inc. Merrimack will not receive any further contingent consideration or royalties as a result of this transaction.
Dec 03, 2019 09:15 am ET
Merrimack Pharmaceuticals Adopts Section 382 Net Operating Loss Rights Plan
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (the “Company” or “Merrimack”), announced today that its Board of Directors (the “Board”) has adopted a Section 382 net operating loss rights plan (the “Plan”) and declared a dividend distribution of one Preferred Share Purchase Right on each outstanding share of Company common stock. The Plan is designed to protect the Company’s ability to use its valuable net operating loss (“NOL”) carryforwards and certain other valuable tax attributes.
Dec 03, 2019 08:45 am ET
Merrimack Receives $5 Million Milestone Payment from Ipsen; Declares $6.7 Million Special Dividend
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that it received a $5 million milestone payment from Ipsen, triggered by Ipsen’s decision to progress the ongoing multi-part clinical trial evaluating ONIVYDE in patients with small-cell lung cancer into the second randomized portion of the trial focused on efficacy assessment. As a result of this milestone payment, Merrimack’s Board of Directors has authorized and declared a special cash dividend of $6.7 million on the Company’s common stock (the “Special Dividend”).
Sep 24, 2019 04:45 pm ET
JFL Capital Ends Campaign at Merrimack
LAKEWAY, Texas, Sept. 24, 2019 /PRNewswire/ -- JFL Capital Management, LLC (together with its affiliates, "JFL Capital"), the largest stockholder of Merrimack Pharmaceuticals, Inc. ("Merrimack" or the "Company") (NASDAQ: MACK), with ownership of approximately 9.4% of the Company's outstanding shares, announced today that it has withdrawn its solicitation in connection with the Company's 2019 annual meeting of stockholders (the "Annual Meeting").
Sep 19, 2019 09:00 am ET
Merrimack Pharmaceuticals Announces Changes to Board of Directors
Merrimack Pharmaceuticals (Nasdaq:MACK) (the “Company” or “Merrimack”) announced today that, effective immediately, its Board of Directors has appointed Noah G. Levy, of Newtyn Management, LLC (“Newtyn”) and Eric D. Andersen, of Western Standard, LLC (“Western”) to the Board, pursuant to a cooperation agreement.
Sep 05, 2019 09:15 am ET
Merrimack Pharmaceuticals Announces Per Share Amount for Previously Declared Special Dividend
Merrimack Pharmaceuticals (Nasdaq: MACK) (the “Company” or “Merrimack”) announced today that the dividend amount for the previously authorized and declared $20 million special cash dividend (the “Special Dividend”) announced on July 25, 2019 is $1.496675 per outstanding share of Merrimack common stock. The dividend will be paid today, September 5, 2019, as previously announced, to stockholders of record as of the close of business on August 28, 2019.
Aug 26, 2019 09:00 am ET
Merrimack Pharmaceuticals Issues Letter to Shareholders
The Board of Directors of Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (the “Company” or “Merrimack”) today issued a letter to shareholders in connection with the Company’s upcoming 2019 Annual Meeting of Shareholders (the “2019 Annual Meeting”), which is scheduled to be held on October 17, 2019.
Aug 22, 2019 08:30 am ET
JFL Capital Issues Letter to Fellow Merrimack Stockholders
LAKEWAY, Texas, Aug. 22, 2019 /PRNewswire/ -- JFL Capital Management, LLC, together with its affiliates and the other participants in its solicitation, the largest stockholder of Merrimack Pharmaceuticals, Inc. ("Merrimack" or the "Company") (NASDAQ: MACK), with ownership of approximately 18.7% of the Company's outstanding shares, announced today that it has issued a letter to Merrimack stockholders in connection with the Company's upcoming annual meeting of stockholders that has been delayed until October 17, 2019.
Aug 16, 2019 09:15 am ET
Merrimack Pharmaceuticals Reschedules 2019 Annual Meeting of Shareholders for October 17, 2019
Merrimack Pharmaceuticals (Nasdaq: MACK) (the “Company” or “Merrimack”) announced today it is rescheduling its 2019 Annual Meeting of Shareholders (the “2019 Annual Meeting”) for October 17, 2019. As a result, the record date for the 2019 Annual Meeting will now be September 16, 2019.
Jul 25, 2019 08:30 am ET
Merrimack Declares $20 Million Special Dividend
CAMBRIDGE, Mass., July 25, 2019 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that its Board of Directors has authorized and declared a special cash dividend of $20 million on the Company's common stock.
May 10, 2019 07:30 am ET
Merrimack Reports First Quarter 2019 Financial Results
CAMBRIDGE, Mass., May 10, 2019 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), an oncology company focused on biomarker-defined cancers, today announced its first quarter 2019 financial results for the period ended March 31, 2019.
Apr 18, 2019 03:07 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Merrimack Pharmaceuticals, Inc. - MACK
Pomerantz LLP is investigating claims on behalf of investors of Merrimack Pharmaceuticals, Inc. (“Merrimack” or the “Company”) (NASDAQ: MACK).   Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529,...
Apr 16, 2019 07:10 am ET
Report: Developing Opportunities within Eastman Chemical, Target, Federated Investors, First American Financial, Merrimack Pharmaceuticals, and LyondellBasell Industries N.V — Future Expectations, Pro
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Eastman Chemical Company (NYSE:EMN), Target Corporation (NYSE:TGT),...
Apr 12, 2019 01:57 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Merrimack Pharmaceuticals, Inc. - MACK
Pomerantz LLP is investigating claims on behalf of investors of Merrimack Pharmaceuticals, Inc. (“Merrimack” or the “Company”) (NASDAQ: MACK).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529,...
Apr 09, 2019 05:50 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Merrimack Pharmaceuticals, Inc. - MACK
NEW YORK, April 9, 2019 /CNW/ -- Pomerantz LLP is investigating claims on behalf of investors of Merrimack Pharmaceuticals, Inc. ("Merrimack" or the "Company") (NASDAQ: MACK).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.
Apr 09, 2019 05:50 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Merrimack Pharmaceuticals, Inc. - MACK
NEW YORK, April 9, 2019 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Merrimack Pharmaceuticals, Inc. ("Merrimack" or the "Company") (NASDAQ: MACK).  Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.
Apr 04, 2019 04:15 pm ET
Merrimack Discontinues Development of MM-310
CAMBRIDGE, Mass., April 4, 2019 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), an oncology company focused on biomarker-defined cancers, today announced the Company is discontinuing development of MM-310, its antibody-directed nanotherapeutic for the treatment of solid tumors. This decision was the result of a comprehensive review of available safety data from its Phase 1 study. Based on emerging data since the recent amendment of the clinical protocol, the Company has concluded that the study would not be able to reach an optimal therapeutic index for MM-310. Merrimack has
Mar 06, 2019 06:00 am ET
Merrimack Reports Fourth Quarter and Full Year 2018 Financial Results
CAMBRIDGE, Mass., March 6, 2019 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced its fourth quarter and full year 2018 financial results for the period ended December 31, 2018.
Dec 10, 2018 05:00 pm ET
John M. Dineen Appointed to Syneos Health Board of Directors, Named Chairman
Syneos Health™ (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that John M. Dineen has been appointed to the Company’s Board of Directors and named Chairman of the Board. Dineen succeeds Michael A....
Nov 09, 2018 08:45 am ET
Research Report Identifies Merrimack Pharmaceuticals, PNM Resources, Inc. (Holding Co.), Carrols Restaurant Group, American Axle & Manufacturing, CBIZ, and Nova Measuring Instruments with Renewed Outl
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), PNM Resources, Inc....
Nov 07, 2018 05:45 am ET
Merrimack Reports Third Quarter 2018 Financial Results and Provides Strategic Update Following Portfolio Review
CAMBRIDGE, Mass., Nov. 7, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a research and clinical development oncology company focused on biomarker-defined cancers, today announced its third quarter 2018 financial results for the period ended September 30, 2018 and provided a strategic update.
Oct 31, 2018 04:05 pm ET
Merrimack Announces Timing of Third Quarter 2018 Investor Conference Call
CAMBRIDGE, Mass., Oct. 31, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will host its third quarter 2018 investor conference call and webcast at 8:30 am ET on Wednesday, November 7, 2018.  
Oct 19, 2018 06:00 am ET
Merrimack Discontinues Phase 2 SHERLOC Study of MM-121 in Patients with Non-Small Cell Lung Cancer Due to Futility
CAMBRIDGE, Mass., Oct. 19, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced the termination of the SHERLOC study, its randomized, open-label Phase 2 clinical trial evaluating MM-121 in combination with docetaxel in patients with heregulin positive NSCLC.
Oct 16, 2018 07:30 am ET
Detailed Research: Economic Perspectives on Clearside Biomedical, JELD-WEN Holding, L.B. Foster, Merrimack Pharmaceuticals, Everi, and Drive Shack — What Drives Growth in Today's Competitive Landscape
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Clearside Biomedical, Inc. (NASDAQ:CLSD), JELD-WEN Holding, Inc....
Sep 20, 2018 07:00 am ET
Merrimack Receives $5 Million Milestone Payment from Shire
CAMBRIDGE, Mass., Sept. 20, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced that it has received a $5 million milestone payment from Shire, triggered by the sale of ONIVYDE in the first major non-European, non-Asian country, pursuant to the terms of Merrimack's asset sale to Ipsen in 2017.
Sep 06, 2018 06:50 am ET
Merrimack Completes Enrollment in Randomized Phase 2 SHERLOC Study of MM-121 (seribantumab) in Non-Small Cell Lung Cancer (NSCLC)
CAMBRIDGE, Mass., Sept. 6, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced that it has completed enrollment in its ongoing SHERLOC study, a Phase 2 clinical trial evaluating its lead investigational drug candidate, MM-121, in patients with heregulin positive NSCLC.
Aug 16, 2018 08:00 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Celsion, Alpha and Omega Semiconductor, SP Plus, Merrimack Pharmaceuticals, La Jolla Pharmaceutical, and SPX — New Research Emphasiz
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Celsion Corporation (NASDAQ:CLSN), Alpha and Omega Semiconductor Limited...
Aug 07, 2018 06:30 am ET
Merrimack Reports Second Quarter 2018 Financial Results
CAMBRIDGE, Mass., Aug. 7, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced its second quarter 2018 financial results for the period ended June 30, 2018.
Jul 31, 2018 04:10 pm ET
Merrimack Announces Timing of Second Quarter 2018 Investor Conference Call
CAMBRIDGE, Mass., July 31, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will host its second quarter 2018 investor conference call and webcast at 8:30 am ET on Tuesday, August 7, 2018.  
Jul 02, 2018 04:15 pm ET
Merrimack Secures $25 Million Debt Facility with Hercules Capital
CAMBRIDGE, Mass., July 2, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced the closing of a $25 million term loan with Hercules Capital (NYSE: HTGC), $15 million of which was funded at closing today. Merrimack's current cash and cash equivalents, including the $15 million of loan proceeds received, and certain potential net milestone payments anticipated from Shire are projected to fund the company's planned operations into the first quarter of 2020.
Jun 25, 2018 07:20 am ET
Merrimack Announces Top-Line Results from Randomized Phase 2 Trial of MM-141 in Front-Line Metastatic Pancreatic Cancer
CAMBRIDGE, Mass., June 25, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced top-line results from the CARRIE study, a randomized Phase 2 trial evaluating the addition of MM-141 (istiratumab) to standard-of-care treatment in patients with previously untreated metastatic pancreatic cancer and high serum levels of free Insulin-like Growth Factor-1 (IGF-1). The study did not meet its primary or secondary efficacy endpoints in patients who received MM-141 in combination with nab-paclitaxel
May 29, 2018 08:15 am ET
Research Report Identifies AngioDynamics, Kaiser Aluminum, Mammoth Energy Services, Meridian Bioscience, Merrimack Pharmaceuticals, and Energizer with Renewed Outlook — Fundamental Analysis, Calculati
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AngioDynamics, Inc. (NASDAQ:ANGO), Kaiser Aluminum Corporation...
May 29, 2018 07:00 am ET
Merrimack to Present at the 2018 American Society of Clinical Oncology Annual Meeting
CAMBRIDGE, Mass., May 29, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced that it will present two posters at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 1-5, 2018 at McCormick Place North/South in Chicago.
May 01, 2018 07:00 am ET
Merrimack Announces Timing of First Quarter 2018 Investor Conference Call
CAMBRIDGE, Mass., May 1, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will host its first quarter 2018 investor conference call and webcast at 8:30 am ET on Tuesday, May 8, 2018.  
Apr 09, 2018 07:30 am ET
Merrimack to Present Preclinical Data at the 2018 American Association for Cancer Research Annual Meeting
CAMBRIDGE, Mass., April 9, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced that it will present preclinical data at the 2018 American Association for Cancer Research (AACR) Annual Meeting, April 14-18, 2018 at McCormick Place North/South in Chicago. Of particular focus will be preclinical data on MM-310, an antibody-directed nanotherapeutic (ADN) that is currently being evaluated in a Phase 1 study in solid tumors.
Apr 04, 2018 08:15 am ET
Consolidated Research: 2018 Summary Expectations for Merrimack Pharmaceuticals, Monroe Capital, NL Industries, FCB Financial, Amtech, and Otter Tail — Fundamental Analysis, Key Performance Indications
NEW YORK, April 04, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), Monroe Capital...
Mar 12, 2018 06:27 am ET
Merrimack Provides Business Update and Reports 2017 Financial Results
CAMBRIDGE, Mass., March 12, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced its fourth quarter and full year 2017 financial results for the period ended December 31, 2017.
Mar 12, 2018 06:25 am ET
Merrimack Strengthens SHERLOC Study of MM-121 in Non-small Cell Lung Cancer
CAMBRIDGE, Mass., March 12, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced that it is expanding enrollment in the ongoing randomized Phase 2 SHERLOC study of its investigational drug candidate MM-121 in patients with heregulin-positive non-small cell lung cancer who have progressed after a platinum-containing regimen.
Mar 05, 2018 06:00 am ET
Merrimack Announces Timing of Full Year 2017 Investor Conference Call and Presentation at the Cowen Health Care Conference
CAMBRIDGE, Mass., March 5, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will host its fourth quarter and full year 2017 investor conference call and webcast at 8:30 a.m. ET on Monday, March 12, 2018.
Feb 26, 2018 05:55 am ET
Merrimack Doses First Patient in Randomized Phase 2 Clinical Study of MM-121 in Patients with Post-Menopausal Metastatic Breast Cancer
CAMBRIDGE, Mass., Feb. 26, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced that it has dosed the first patient in its SHERBOC study, a double-blind, placebo-controlled randomized Phase 2 clinical trial of MM-121 (seribantumab) in patients with heregulin-positive, hormone receptor-positive and HER2-negative post-menopausal metastatic breast cancer. MM-121 is a fully human monoclonal antibody that targets HER3 signaling and is designed to overcome cancer cells' resistance to the effects
Feb 20, 2018 06:00 am ET
Merrimack Announces Formation of New Scientific Advisory Board with Extensive Expertise in Precision Oncology
CAMBRIDGE, Mass., Feb. 20, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced the formation of a new Scientific Advisory Board (SAB), comprised of world-renowned experts in precision oncology, including expertise in biomarker-defined cancers, bioengineering, drug discovery and clinical development. The SAB will work closely with Merrimack's senior management team to advance the company's robust pipeline of targeted cancer therapies.
Feb 15, 2018 06:00 am ET
Merrimack to Present at the 2018 RBC Capital Markets Global Healthcare Conference
CAMBRIDGE, Mass., Feb. 15, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals (Nasdaq: MACK), a clinical-stage oncology company focused on biomarker-defined cancers, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, is scheduled to present at the 2018 RBC Capital Markets Global Healthcare Conference on Thursday, February 22, 2018, at 9:30 a.m. ET in New York.
Feb 06, 2018 08:25 am ET
New Research Coverage Highlights Atara Biotherapeutics, SPX, Entellus Medical, Columbus McKinnon, NantKwest, and Merrimack Pharmaceuticals — Consolidated Revenues, Company Growth, and Expectations for
NEW YORK, Feb. 06, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Atara Biotherapeutics, Inc. (NASDAQ:ATRA), SPX Corporation...
Jan 04, 2018 07:00 am ET
Merrimack to Present at the 36th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 4, 2018 /PRNewswire/ -- Merrimack Pharmaceuticals (NASDAQ: MACK) today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, is scheduled to present at the 36th Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2018, at 9:00 a.m. PT in San Francisco.
Nov 30, 2017 05:50 am ET
Merrimack Announces Appointment of George Demetri, M.D., to Board of Directors
CAMBRIDGE, Mass., Nov. 30, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals (NASDAQ: MACK) today announced the addition of George Demetri, M.D., a professor of medicine at Harvard Medical School and physician-scientist faculty member at the Dana-Farber Cancer Institute (DFCI), to its Board of Directors. Dr. Demetri, a world-renowned expert in the clinical translation of innovative treatment strategies for cancer, replaces John Mendelsohn, M.D., who is retiring from the Board.
Nov 14, 2017 07:00 am ET
Torque, a Flagship Pioneering Company, Launches Platform to Develop a New Class of Deep-Primed™ Immune Cell Therapies, Financed with $25M Series A and Led by a Veteran Management Team
CAMBRIDGE, Mass., Nov. 14, 2017 /PRNewswire/ -- Torque, an immuno-oncology company developing Deep Primed™ cell therapies that direct and evoke immune responses in the tumor microenvironment, today announced the launch of its technology platform to create a new class of immune cell therapeutics to treat cancer, financed with $25 million in Series A capital by Flagship Pioneering. The Torque platform makes it possible to anchor powerful stimulatory cytokines, antibodies, and small molecules directly to immune cells to direct their activity and increase their efficacy and durability in the "ho
Nov 08, 2017 06:40 am ET
Merrimack Reports Third Quarter 2017 Financial Results
CAMBRIDGE, Mass., Nov. 8, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced its third quarter 2017 financial results for the period ended September 30, 2017.
Nov 01, 2017 07:55 am ET
Merrimack Announces Timing of Third Quarter 2017 Investor Conference Call
CAMBRIDGE, Mass., Nov. 1, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will host its third quarter 2017 investor conference call and webcast at 8:30 am ET on Wednesday, November 8, 2017.   
Oct 30, 2017 07:55 am ET
Merrimack Receives Orphan Drug Designation for MM-121 for the Treatment of Heregulin Positive Non-small Cell Lung Cancer
CAMBRIDGE, Mass., Oct. 30, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MM-121, its investigational drug candidate, for the treatment of heregulin positive non-small cell lung cancer. MM-121 (seribantumab) is a fully human monoclonal antibody designed to block tumor survival signals and enhance the anti-tumor effect of combination therapies by targeting the cell surface receptor HER3 (ErbB3) in patients with high expression of the biomarker heregulin.
Oct 13, 2017 08:30 am ET
Merrimack Commences Tender Offer for Any and All of its Outstanding 4.50% Convertible Senior Notes Due 2020
CAMBRIDGE, Mass., Oct. 13, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals (NASDAQ: MACK) (the "Company" or "Merrimack") today announced that it has commenced a tender offer (the "Tender Offer") to purchase any and all of its $25,031,000 aggregate principal amount of outstanding 4.50% Convertible Senior Notes due 2020 (CUSIP No. 590328AA8; ISIN No. US590328AA86) (the "Notes"), which amount reflects the consummation of the purchase of the Notes from the Settlement Noteholders (as defined herein) pursuant to the Settlement Agreement (as defined herein). The Company agreed to conduct the Tender
Oct 10, 2017 05:23 pm ET
Merrimack Announces Settlement of Convertible Note Litigation
CAMBRIDGE, Mass., Oct. 10, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals (NASDAQ: MACK) today announced that it has reached a settlement agreement with Wolverine Flagship Fund Trading Limited, 1992 MSF International Ltd. and 1992 Tactical Credit Master Fund, L.P. (collectively, "Noteholder Plaintiffs") and Wells Fargo Bank, National Association, to resolve the previously disclosed lawsuit captioned Wells Fargo Bank, N.A., et. al. v. Merrimack Pharmaceuticals, Inc. pending in the Court of Chancery in the State of Delaware (the "Delaware Action").
Aug 31, 2017 09:00 am ET
Merrimack Announces Date of One-for-Ten Reverse Stock Split
CAMBRIDGE, Mass., Aug. 31, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals (NASDAQ: MACK) today announced that the previously disclosed one-for-ten reverse stock split of its issued and outstanding common stock will be effective for trading purposes as of the commencement of trading on September 6, 2017. Merrimack's stockholders approved an amendment to the Company's certificate of incorporation to effect the reverse stock split at the Annual Meeting of Stockholders on August 11, 2017.
Aug 14, 2017 07:55 am ET
Merrimack Augments Executive Team with Appointment of Jean Franchi as Chief Financial Officer
CAMBRIDGE, Mass., Aug. 14, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals (NASDAQ: MACK) today announced that it has strengthened its executive management team with the appointment of Jean M. Franchi as Chief Financial Officer, effective August 21, 2017. In this role, Ms. Franchi will plan and oversee Merrimack's financial strategy to support the ongoing development of multiple clinical- and preclinical-stage product candidates for cancer.
Aug 09, 2017 07:55 am ET
Merrimack Reports Second Quarter 2017 Financial Results
CAMBRIDGE, Mass., Aug. 9, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced its second quarter 2017 financial results for the period ended June 30, 2017.
Aug 02, 2017 08:00 am ET
Merrimack Announces Timing of Second Quarter 2017 Investor Conference Call
CAMBRIDGE, Mass., Aug. 2, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will host its second quarter 2017 investor conference call and webcast at 8:30 am ET on Wednesday, August 9, 2017.  
Jul 24, 2017 07:55 am ET
Merrimack Appoints Thomas Needham as Chief Business Officer
CAMBRIDGE, Mass., July 24, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals (NASDAQ: MACK) today announced  further expansion of its executive management team with the appointment of Thomas E. Needham, Jr., M.B.A., to the position of Chief Business Officer. In this role, Mr. Needham will help design and implement Merrimack's strategy for its broad pipeline of clinical and preclinical development assets.
Jun 19, 2017 07:55 am ET
Merrimack Announces Completion of Enrollment in Phase 2 CARRIE Study of MM-141; Data Expected in First Half of 2018
CAMBRIDGE, Mass., June 19, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that it has enrolled the last patient in the ongoing CARRIE study, a Phase 2, double-blind, placebo-controlled, randomized trial, evaluating MM-141 (istiratumab) in combination with standard of care in previously untreated patients with metastatic pancreatic cancer.  MM-141 is a bispecific antibody targeting both the Insulin Like Growth Factor 1 Receptor (IGF-1R) and the HER3 receptor, and is a potent inhibitor of the PI3K/AKT/mTOR signaling pathway.
Jun 08, 2017 07:55 am ET
Merrimack Announces Expansion of Senior Management Team with Appointment of Sergio Santillana as Chief Medical Officer and Ellen Forest as Head of Human Resources
CAMBRIDGE, Mass., June 8, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced the expansion of its senior management team through the addition of two new executive hires. Sergio L. Santillana, M.D., MSc, a medical oncologist with extensive industry experience leading a wide range of clinical development programs, has been appointed to the role of Chief Medical Officer, effective June 12, 2017.  In addition, Ellen K. Forest, who served most recently as Director of Human Resources at Baxalta, has joined Merrimack to lead its talent and recruitment strategy as th
May 25, 2017 05:30 pm ET
Merrimack Announces Management Change
CAMBRIDGE, Mass., May 25, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced the resignation of Dr. Yasir Al-Wakeel as Chief Financial Officer and Head of Corporate Development, effective June 9, 2017. Dr. Al-Wakeel, who has been in his role with Merrimack since August 2015, is leaving to pursue other business interests. Merrimack has initiated a search to appoint a new chief financial officer.
May 10, 2017 07:45 am ET
Merrimack Reports First Quarter 2017 Financial Results
CAMBRIDGE, Mass., May 10, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced its first quarter 2017 financial results for the period ended March 31, 2017.
May 02, 2017 05:30 pm ET
Merrimack Announces Timing of First Quarter 2017 Investor Conference Call
CAMBRIDGE, Mass., May 2, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will host its first quarter 2017 investor conference call and webcast at 8:30 am ET on Wednesday, May 10, 2017.   
Apr 17, 2017 08:00 am ET
Merrimack Appoints Daryl Drummond, Ph.D. as Head of Research
CAMBRIDGE, Mass., April 17, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that Daryl Drummond, Ph.D. has been appointed Head of Research. Dr. Drummond, an expert and pioneer in the field of nanotherapeutics, has held various leadership roles at Merrimack, including most recently as Vice President of Discovery and Team Leader for Merrimack's early-stage pipeline. Dr. Drummond was also integral in the invention and development of ONIVYDE®, which was recently sold to Ipsen S.A. for up to $1.025 billion.
Apr 05, 2017 05:05 pm ET
Merrimack Declares $140M Special Dividend in Connection with Recently Completed Asset Sale
CAMBRIDGE, Mass., April 5, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that its Board of Directors has authorized and declared a special cash dividend of $140 million on the company's common stock. This special dividend will be paid from the proceeds of the company's asset sale to Ipsen S.A., which was completed on April 3, 2017.
Apr 03, 2017 12:30 pm ET
Merrimack Launches as New, Refocused Research & Clinical Development Company with Resources to Advance Prioritized Lead Pipeline Candidates MM-121, MM-141 and MM-310
CAMBRIDGE, Mass., April 3, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that it has commenced operating as a new, refocused research and clinical development company in connection with the completion today of its previously announced transaction with Ipsen S.A. valued at up to $1.025 billion. Under the terms of the agreement, Merrimack sold to Ipsen its first commercial product, ONIVYDE®, including U.S. commercialization rights and its licensing agreement with Shire plc, and its development, license and supply agreement with Actavis for a generic versio
Mar 30, 2017 01:00 pm ET
Merrimack Stockholders Approve Sale of ONIVYDE® and Generic Version of DOXIL® to Ipsen for Up to $1.025 Billion
CAMBRIDGE, Mass., March 30, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) ("Merrimack") announced that, at its Special Meeting of Stockholders held today, its stockholders voted to approve the asset sale with Ipsen S.A. under which Merrimack will:
Mar 27, 2017 08:00 am ET
Merrimack to Present at the 2017 American Association for Cancer Research Annual Meeting
CAMBRIDGE, Mass., March 27, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that it will present preclinical and clinical data from its oncology pipeline at the 2017 American Association for Cancer Research (AACR) Annual Meeting, April 1-5, 2017 at the Walter E. Washington Convention Center, Washington, D.C.. Of particular focus will be data on MM-310, an antibody-directed nanotherapeutic (ADN) that entered clinical development last week with the initiation of a Phase 1 study in solid tumors.
Mar 23, 2017 08:00 am ET
Merrimack Initiates Phase 1 Study of MM-310 in Solid Tumors
CAMBRIDGE, Mass., March 23, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced the enrollment of its first patient in a Phase 1 study of MM-310 in solid tumors. MM-310 is an antibody-directed nanotherapeutic (ADN) that encapsulates a novel taxane and targets the EphA2 receptor, a protein which surveys suggest is overexpressed in 50-100% of many major tumor types, including prostate, ovarian, bladder, gastric, pancreatic and lung cancers.
Mar 01, 2017 07:00 am ET
Merrimack Reports Fourth Quarter and Full-Year 2016 Financial Results
CAMBRIDGE, Mass., March 1, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced its fourth quarter and full year 2016 financial results for the period ended December 31, 2016.
Feb 22, 2017 04:05 pm ET
Merrimack Announces Timing of Fourth Quarter 2016 Investor Conference Call
CAMBRIDGE, Mass., Feb. 22, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will host its Fourth Quarter 2016 investor conference call and webcast at 8:30 a.m., Eastern time, on Wednesday, March 1.   
Jan 18, 2017 07:30 am ET
Merrimack Names Richard Peters, M.D., Ph.D., as President and CEO
CAMBRIDGE, Mass., Jan. 18, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) ("Merrimack" or the "Company") today announced that Richard Peters, M.D., Ph.D., has been appointed as the Company's President and Chief Executive Officer, effective February 6, 2017, at which time he will also be appointed to the Merrimack Board of Directors. Dr. Peters will join Merrimack from his current role at Sanofi Genzyme, where he serves as Senior Vice President and Head of Global Rare Diseases.  He replaces Gary Crocker, Chairman and Interim President and CEO, who guided the Company durin
Jan 08, 2017 07:45 pm ET
Merrimack Concludes Strategic Review; Announces Plan to Divest Assets and Sharpen Strategic Focus
CAMBRIDGE, Mass., Jan. 8, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) ("Merrimack" or the "Company") today announced that it has entered into a definitive asset purchase and sale agreement with Ipsen (Euronext: IPN; ADR: IPSEY) for a transaction valued at up to $1.025 billion, plus up to $33 million in net milestone payments retained by Merrimack pursuant to Merrimack's exclusive licensing agreement with Shire, under which Merrimack will:
Jan 04, 2017 04:10 pm ET
Merrimack to Present at the 35th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 4, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that it will present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, California on Wednesday, January 11, 2017, at 3:00 PM Pacific Time.
Dec 21, 2016 06:55 am ET
Merrimack Stops the Phase 2 HERMIONE Trial of MM-302 in HER2-Positive Metastatic Breast Cancer Patients
CAMBRIDGE, Mass., Dec. 21, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that, following a recent independent Data and Safety Monitoring Board (DSMB) recommendation and subsequent futility analysis, it has decided to stop the Phase 2 HERMIONE study of MM-302 (HER2 antibody-targeted liposomal doxorubicin) in HER2-positive metastatic breast cancer patients who had previously been treated with trastuzumab (Herceptin®), pertuzumab (Perjeta®) and ado-trastuzumab emtansine (T-DM1, Kadcyla®).
Nov 09, 2016 04:02 pm ET
Merrimack Reports Third Quarter 2016 Financial Results
CAMBRIDGE, Mass., Nov. 9, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced its third quarter 2016 financial results. Merrimack will host a live conference call and webcast today, Wednesday, November 9 at 4:30 p.m., Eastern time, to provide an update on Merrimack's progress as well as a summary of these results.
Nov 07, 2016 09:31 am ET
Tesla Motors, Spark Therapeutics, SolarCity, Lululemon, and Merrimack Pharmaceuticals and more offer option-trading opportunities that offer returns of more than 20%
CHICAGO, Nov. 7, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LULU, MACK, ONCE, SCTY, and TSLA.
Nov 02, 2016 05:15 pm ET
Merrimack Announces Timing of Third Quarter 2016 Investor Conference Call
CAMBRIDGE, Mass., Nov. 2, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will host its Third Quarter 2016 investor conference call and webcast at 4:30 p.m., Eastern time, on Wednesday, November 9.   
Oct 31, 2016 08:30 am ET
Merrimack Announces Acceptance for Review of ANDA filed by Actavis for Generic Doxorubicin Hydrochloride Liposome Injection (aka DOXIL®)
CAMBRIDGE, Mass., Oct. 31, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Abbreviated New Drug Application (ANDA) for generic doxorubicin hydrochloride (HCI) liposome injection submitted by its partner Actavis LLC (an indirect, wholly owned subsidiary of Teva Pharmaceuticals USA, Inc.). This is the first product developed by Merrimack under a partnership agreement with Actavis LLC pursuant to which Merrimack is responsible for the development and commercial supply of bulk drug pr
Oct 21, 2016 12:00 pm ET
Covered Call reports for Gilead Sciences, American Express, Petrobras, Merrimack Pharmaceuticals and Intra-Cellular Therapies include trade ideas that offer returns of 20% or more!
CHICAGO, Oct. 21, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AXP, GILD, ITCI, MACK, and PBR.
Oct 11, 2016 08:30 am ET
Final Results of NAPOLI-1 Study Confirm Overall Survival and Progression-Free Survival Benefit for the ONIVYDE® Regimen for Patients with Metastatic Pancreatic Cancer
CAMBRIDGE, Mass., Oct. 11, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced final results from the pivotal Phase 3 NAPOLI-1 study validating the use of ONIVYDE® (irinotecan liposome injection) in combination with fluorouracil (5-FU) and leucovorin, which represents a new standard of care for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) following treatment with gemcitabine-based therapy. The final NAPOLI-1 results were presented in a poster discussion session and a separate analysis of NAPOLI-1 safety-over-time data was presented in a po
Oct 03, 2016 08:15 am ET
Merrimack Announces Major Corporate Restructuring
CAMBRIDGE, Mass., Oct. 3, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced a major corporate restructuring with the objective of prioritizing its research and development on a focused set of systems biology-derived oncology products and strengthening its financial runway.  As part of this move, Merrimack is immediately implementing a 22% reduction in headcount and eliminating more than $200 million in expected costs over the next two years. In line with this restructuring, the Board of Directors has accepted the resignation of President and CEO Robert Mulro
Sep 28, 2016 05:09 pm ET
Merrimack to Present Final Results of Phase 3 NAPOLI-1 Study at the European Society for Medical Oncology 2016 Congress
CAMBRIDGE, Mass., Sept. 28, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced it will present six posters from its systems-biology derived antibody engineering and nanotherapeutic portfolios at the European Society for Medical Oncology (ESMO) 2016 Congress, October 7 – 11, 2016 in Copenhagen, Denmark.  
Sep 27, 2016 10:31 am ET
Learn how to target a 20% return on Chipotle Mexican Grill, or get option-trade ideas on Merrimack Pharmaceuticals, Lumentum Holdings, US Steel and Oracle Corporation or any stock you choose
CHICAGO, Sept. 27, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CMG, LITE, MACK, ORCL, and X.
Sep 21, 2016 10:31 am ET
Apple trade offers a 4% return in 30 days, or find similar option trades on Wells Fargo & Co., Marriott International, Starwood Hotels & Resorts Worldwide, and Merrimack Pharmaceuticals
CHICAGO, Sept. 21, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, HOT, MACK, MAR, and WFC.
Aug 15, 2016 10:31 am ET
Aug 05, 2016 10:31 am ET
Aug 04, 2016 05:01 pm ET
Merrimack Reports Second Quarter 2016 Financial Results
CAMBRIDGE, Mass., Aug. 4, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced its second quarter 2016 financial results. Merrimack will host a live conference call and webcast today, Thursday, August 4 at 4:30 p.m., Eastern time, to provide an update on Merrimack's progress as well as a summary of these results.
Jul 25, 2016 03:01 am ET
Merrimack Announces ONIVYDE® Regimen Receives Positive CHMP Opinion in European Union
CAMBRIDGE, Mass., July 25, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for ONIVYDE® (irinotecan liposome injection), also known as "nal-IRI", in combination with fluorouracil (5-FU) and leucovorin for the treatment of patients with metastatic pancreatic adenocarcinoma who have progressed after gemcitabine-based therapy. The CHMP positive opinion for ONIVYDE will now be reviewed by the European Commission (EC) for marketing
Jul 19, 2016 05:05 pm ET
Merrimack Announces Timing of Second Quarter 2016 Investor Conference Call
CAMBRIDGE, Mass., July 19, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK)  today announced that the company will host its Second Quarter 2016 Investor Conference Call and webcast at 4:30 p.m., Eastern time, on Thursday, August 4.   
Jul 06, 2016 09:00 am ET
FDA Grants Merrimack Fast Track Designation for Seribantumab (MM-121) in Non-small Cell Lung Cancer
CAMBRIDGE, Mass., July 6, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the U.S. Food and Drug Administration (FDA) has granted seribantumab, also known as MM-121, Fast Track designation for development in patients with heregulin-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has progressed following immunotherapy. Fast Track is a program designed by the FDA to facilitate and expedite the development and review of drugs that treat serious conditions and fill an unmet medical need. Merrimack is conductin
Jun 30, 2016 09:00 am ET
NAPOLI-1 Data Demonstrates ONIVYDE® Regimen Maintains Quality of Life While Improving Overall Survival in Patients with Metastatic Pancreatic Cancer
CAMBRIDGE, Mass., June 30, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced a newly presented analysis of the Phase 3 NAPOLI-1 data shows patients treated with ONIVYDE® (irinotecan liposome injection), also known as "nal-IRI," in combination with fluorouracil (5-FU) and leucovorin, maintain similar baseline quality of life at 12 weeks despite the addition of a second chemotherapeutic agent when compared to 5-FU and leucovorin alone. These findings were presented in an oral session by Dr. Richard Hubner, an investigator on the NAPOLI-1 trial and a Consultant
Jun 21, 2016 05:32 pm ET
Merrimack to Present New Analyses of Phase 3 NAPOLI-1 Data at the ESMO 18th World Congress on Gastrointestinal Cancer
CAMBRIDGE, Mass., June 21, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that it will present new analyses of the Phase 3 NAPOLI-1 data in an oral presentation and poster discussion session at the European Society for Medical Oncology  (ESMO) 18th World Congress on Gastrointestinal Cancer, June 29 – July 2, 2016 in Barcelona, Spain. An oral presentation by Dr. Richard Hubner, Consultant Medical Oncologist, The Christie NHS Foundation Trust and investigator on the NAPOLI-1 trial, will compare the effects of ONIVYDE® (also known as "nal-IRI") in combinatio
Jun 06, 2016 08:30 am ET
Final Analysis of First-in-Human Phase 1 Study of MM-151 Shows Positive Clinical Activity in Multiple Solid Tumor Types, Including Colorectal Cancer
CAMBRIDGE, Mass., June 6, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced results from the final analysis of the Phase 1 study of MM-151, a novel investigational oligoclonal epidermal growth factor receptor (EGFR) inhibitor, in patients with refractory solid tumors. These results were presented at a Poster Discussion Session at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
May 19, 2016 08:05 am ET
Merrimack Announces a Leading-edge Biomarker-Selected, Multi-Arm Basket Trial that Matches Patients with Most Appropriate Combination Regimens
CAMBRIDGE, Mass., May 19, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) announced today the initiation of a biomarker-selected, multi-arm Phase 1 clinical study in metastatic colorectal, non-small cell lung, and head and neck cancers. Merrimack's first-of-its-kind basket study will use a combination of genetic and nongenetic biomarkers to match patients to appropriate novel combinations of investigational drug regimens based on their cancer's molecular signature. This approach is expected to enable more than 95 percent of eligible patients to qualify for enrollment to o
May 19, 2016 08:00 am ET
Merrimack and Baxalta Announce Initiation of Phase 1 Study of MM-151 in Combination with the ONIVYDE® (irinotecan liposome injection) Regimen in Metastatic Colorectal Cancer
CAMBRIDGE, Mass. and BANNOCKBURN, Ill., May 19, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) and Baxalta Incorporated (NYSE: BXLT) today jointly announced the initiation of a Phase 1 clinical study of Merrimack's oligoclonal EGFR (epidermal growth factor receptor) inhibitor, MM-151, in combination with ONIVYDE® (irinotecan liposome injection) plus fluorouracil (5-FU) and leucovorin in patients with RAS wild-type metastatic colorectal cancer. Data from a prior Phase 1 study of MM-151 supports further clinical evaluation of the investigational therapy in patients with me
May 18, 2016 06:10 pm ET
Merrimack to Present on Extensive Oncology Pipeline at the 2016 American Society of Clinical Oncology Annual Meeting
CAMBRIDGE, Mass., May 18, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that it will present on its extensive oncology pipeline at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2016 at McCormick Place, Chicago, Illinois. Final results from a Phase 1 study evaluating the safety, pharmacology and initial efficacy of MM-151 will be presented in a Poster Discussion Session. Merrimack will also present on the results from its Phase 3 NAPOLI-1 study of ONIVYDE®, as well as on multiple therapeutic candidates from its antibody en
May 17, 2016 05:05 pm ET
Merrimack Presents Expanded Analysis from Seribantumab (MM-121) Phase 2 Breast Cancer Study at the AACR Precision Medicine Series
CAMBRIDGE, Mass., May 17, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today presented an expanded analysis of its Phase 2 study of seribantumab (MM-121) in combination with exemestane in HER2-negative, hormone receptor positive metastatic breast cancer.  Top line results from this study were announced in 2014. The final analysis, as well as a poster on Merrimack's investigational companion diagnostic for seribantumab, were presented this week at the AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer, in Miami, Florida. 
May 02, 2016 05:01 pm ET
Merrimack Reports First Quarter 2016 Financial Results
CAMBRIDGE, Mass., May 2, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced its first quarter 2016 financial results. Merrimack will host a live conference call and webcast today, Monday, May 2 at 4:30 p.m., Eastern time, to provide an update on Merrimack's progress as well as a summary of these results.
Apr 21, 2016 09:00 am ET
Merrimack Unveils its Latest Antibody Directed Nanotherapeutic, MM-310, at the 2016 AACR Annual Meeting
CAMBRIDGE, Mass., April 21, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced positive data from preclinical studies evaluating MM-310, an antibody directed nanotherapeutic (ADN) that encapsulates a newly engineered form of the highly potent chemotherapy docetaxel as a prodrug in an ephrin receptor A2 (EphA2)-targeted liposome. Preclinical data on MM-310 were presented in an oral presentation and three poster sessions at the 2016 American Association for Cancer Research (AACR) Annual Meeting. The posters can be accessed on Merrimack's website.
Apr 20, 2016 05:30 pm ET
Merrimack Announces Timing of First Quarter 2016 Investor Conference Call
CAMBRIDGE, Mass., April 20, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will host its First Quarter 2016 Investor Conference Call and webcast at 4:30 p.m., Eastern time, on Monday, May 2.
Apr 14, 2016 05:05 pm ET
Leica Biosystems and Merrimack Pharmaceuticals to Collaborate on Development of a Heregulin Companion Diagnostic for Seribantumab
NEWCASTLE UPON TYNE, England and CAMBRIDGE, Mass., April 14, 2016 /PRNewswire/ -- Leica Biosystems and Merrimack Pharmaceuticals (NASDAQ: MACK) today announced a strategic partnership to develop companion diagnostic assays to aid in identification of patients who might best respond to current and future oncology therapies developed by Merrimack. The assays will be designed using Advanced Cell Diagnostics' (ACD's) RNAscope technology and will be processed on Leica Biosystems' BOND clinical advanced staining systems.
Mar 24, 2016 08:00 am ET
Merrimack Announces Inclusion of ONIVYDE® (irinotecan liposome injection) as a Category 1 Treatment Option in the 2016 NCCN Guidelines for Pancreatic Adenocarcinoma
CAMBRIDGE, Mass., March 24, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced the National Comprehensive Cancer Network (NCCN) has included ONIVYDE® (irinotecan liposome injection) in combination with fluorouracil (5-FU) and leucovorin in its 2016 Clinical Practice Guidelines in Oncology for pancreatic adenocarcinoma. The new guidelines recognize the ONIVYDE regimen as a category 1 second-line therapy for patients with metastatic adenocarcinoma of the pancreas who have previously been treated with gemcitabine-based therapy. A category 1 classification repres
Mar 16, 2016 05:45 pm ET
Merrimack to Present on Multiple Oncology Programs at the 2016 American Association for Cancer Research Annual Meeting
CAMBRIDGE, Mass., March 16, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that it will present preclinical and clinical data on its extensive oncology pipeline at the 2016 American Association for Cancer Research (AACR) Annual Meeting, April 16-20, 2016 at the Ernest N. Morial Convention Center, New Orleans, Louisiana. Of particular focus will be preclinical data on the latest novel therapeutic developed from Merrimack's nanoliposome platform and systems biology approach - MM-310, an ephrin receptor A2 (EphA2)-targeted nanoliposome delivering docetaxel.
Mar 02, 2016 09:31 am ET
Covered Call Alerts For AbbVie, Micron, Ohr Pharmaceuticals, Merrimack Pharmaceuticals and BioMarin Pharmaceutical Released By InvestorsObserver
CHICAGO, March 2, 2016 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ABBV, MU, OHRP, MACK and BMRN.
Feb 25, 2016 04:01 pm ET
Merrimack Reports Fourth Quarter 2015 Financial Results
CAMBRIDGE, Mass., Feb. 25, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced its fourth quarter and full year 2015 financial results. Merrimack will host a live conference call and webcast today, Thursday, February 25 at 4:30 p.m., Eastern time, to provide an update on Merrimack's progress as well as a summary of these results.
Feb 17, 2016 08:00 am ET
Merrimack Announces Timing of Fourth Quarter 2015 Investor Conference Call
CAMBRIDGE, Mass., Feb. 17, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK)  today announced that the company will host its Fourth Quarter 2015 Investor Conference Call and webcast at 4:30 p.m., Eastern time, on Thursday, February 25.
Jan 19, 2016 06:58 pm ET
Updated Data Shows ONIVYDE® (irinotecan liposome injection) Combination Regimen Increased One Year Survival by 63% in Patients with Metastatic Pancreatic Cancer
CAMBRIDGE, Mass., Jan. 19, 2016 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that an updated overall survival analysis of the Phase 3 NAPOLI-1 study of ONIVYDE® (irinotecan liposome injection) in combination with fluorouracil (5-FU) and leucovorin achieved a substantial improvement in 12-month overall survival in patients with post-gemcitabine metastatic pancreatic adenocarcinoma when compared to 5-FU and leucovorin alone. These updated data will be presented at the American Society of Clinical Oncology 2016 Gastrointestinal Cancers Symposium (ASCO GI), Janu

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.